BostonGene

You always hear about Next-Generation Sequencing (NGS), but what is it really? Why should you use it and when is it most beneficial? In this episode of #HealthcareUnfiltered, Chadi Nabhan, MD, MBA,FACP, sits down with Joe Lennerz, Chief Scientific Officer at BostonGene, to break down the essentials of NGS. They explore how this powerful technology works, as well as its advantages and potential pitfalls. Watch now: https://lnkd.in/eyTsRzFQ

We are honored to have received four awards from GlobalData Plc across three categories—Innovation, Product Launches, and Marketing—reflecting our continued commitment to revolutionizing cancer care and driving advancements in precision medicine! Read more: https://lnkd.in/gXdSRj9h

Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene will deliver a keynote presentation at the European Federation of Laboratory Medicine Strategic Conference 2024 on Monday, September 23, outlining key strategies for implementing integrated diagnostics, with a focus on interdisciplinary collaboration, administrative alignment, and leveraging real-world data to enhance patient care and streamline payor negotiations. #EFLM #laboratorymedicine #IntegratedDiagnostics https://lnkd.in/eh3BxFFT

We are excited to share that our research has been published in Nature! Our integrated multiomic molecular analysis uncovers key gene expression patterns and tumor evolution dynamics, providing insights that predict improved outcomes and reduced toxicity from combination therapy in patients with relapsed/refractory T-cell lymphomas. “Our findings offer a promising new approach for treating patients with relapsed and refractory T-cell lymphomas, specifically those with the follicular helper T-cell subtype. We are excited about the potential of this combination therapy to improve patient outcomes and expand treatment options in this challenging disease.” - Nathan Fowler, MD, Chief Medical Officer at BostonGene Congratulations to Ekaterina Postovalova, Nikita Kotlov, Alexander Bagaev Olga Kudryashova and all the contributing authors! https://lnkd.in/eKNJmahX

Attend our poster presentations at #ESMO24 to learn more about how BostonGene's comprehensive profiling reveals potential biomarkers and therapeutic targets that expand treatment options and support biomarker-driven clinical trials. Read more: https://lnkd.in/ebep_KwS

We are proud to have received one Gold Stevie for our AI-based digital pathology platform and two Silver Stevies for our Tumor Portrait test and immune system profiling platform in the Stevie Awards for Technology Excellence, known as 'the Olympics for technology.' Read more: https://lnkd.in/ejtYrdax

Attend today’s session, "Designing More Effective Trials with Integrated Immune Profiling of Peripheral Blood and Tumor Tissue", at the 14th Annual World CB & CDx Summit. "Immunotherapy holds transformative potential in oncology, but its success depends on our ability to match the right patients with the right therapies. Our AI-powered platform enables comprehensive immune system profiling to identify key immunological signatures and resistance factors, empowering clinicians to make personalized treatment decisions. Our ultimate goal is to improve patient outcomes by guiding therapies in real-time." - Michael Goldberg, PhD, VP, Research & Development at BostonGene.

We are collaborating with Icahn School of Medicine at Mount Sinai on a prospective precision medicine study of patients with #multiplemyeloma. As part of the study, BostonGene will perform #AI-powered next-generation sequencing to uncover therapeutic vulnerabilities and drive #precisionmedicine therapies. Read more: https://lnkd.in/gZAjFzyC

Join us next week in Boston for the 14th Annual World CB & CDx Summit, where we'll demonstrate our cutting-edge immune system profiling technology. Discover how we're advancing personalized immunotherapy and enabling real-time clinical decision-making. https://lnkd.in/gf5C4Dfk

Meet us at next week at the 22nd Annual Conference of the Japanese Society for Digital Pathology. BostonGene's Chief Scientific Officer, Joe Lennerz, MD, PhD, will lead a session on the evolving landscape of digital pathology and present two abstracts on AI-based imaging analysis technologies to improve patient care. https://lnkd.in/eZP7ck-3